Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIF plus ATRA in elderly patients with MDS-RAEB
ChiCTR-OPC-17011137Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Compound Huangdai Tablet and tretinoin in myelodysplastic syndrome with excess blasts (MDS-EB), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: overall response rate. Planned start May 2017; status: not yet recruiting.
02
Drugs
Compound Huangdai Tablettretinoin
03
Conditions
myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on ChiCTR-OPC-17011137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011137.